1,029
Views
0
CrossRef citations to date
0
Altmetric
Review Article

Expert panel consensus recommendations on the utilization of nebulized budesonide for managing asthma and COPD in both stable and exacerbation stages in Thailand

, MD, , MD, , MD, , MD, , MD, , MD, , MDORCID Icon, , MD, , MD, , MD, , MD, , MD & , MD, PhD show all
Received 15 Jan 2024, Accepted 20 Mar 2024, Published online: 03 Apr 2024

Figures & data

Figure 1. PRISMA diagrams summarizing the literature search process for asthma (A) and COPD (B) studies. DPI: dry powder inhaler; pMDI: pressurized metered dose inhaler; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Figure 1. PRISMA diagrams summarizing the literature search process for asthma (A) and COPD (B) studies. DPI: dry powder inhaler; pMDI: pressurized metered dose inhaler; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Table 1. Clinical studies assessing the efficacy and/or safety of nebulized budesonide in adults with asthma.

Table 2. Clinical studies assessing the efficacy and/or safety of nebulized budesonide in adults with COPD.

Data availability statement

Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data-sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Data for studies directly listed on Vivli can be requested through Vivli at www.vivli.org. Data for studies not listed on Vivli could be requested through Vivli at https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/. AstraZeneca Vivli member page is also available outlining further details: https://vivli.org/ourmember/astrazeneca/.